Materia medica

Junshi Biosciences Announces Approval for Marketing of VV116 in China

Retrieved on: 
月曜日, 1月 30, 2023
Treatment, RNA, Marketing, Zhejiang University, Chemistry, Ministry, Safety, Chinese Academy of Sciences, Drug discovery, RNA-dependent RNA polymerase, COVID-19, Ministry of Science and Technology (Vietnam), National Medical Products Administration, Omicron, III, SSE, Shanghai Institute of Technology, Patient, HIV disease progression rates, Physics, Viral load, RNA polymerase II, Severe acute respiratory syndrome coronavirus 2, HKEX, Development, Infection, Death, Approval, Toxicity, State Key Laboratories, Wuhan Institute of Virology, Diagnosis, Pharmaceutical industry, Science, Virology, Materia medica

SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).

Key Points: 
  • SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).
  • VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase (“RdRp”) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect.
  • Preclinical studies have shown that VV116 exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity.
  • The study was led by academician Lanjuan LI, Director of the State Key Laboratory for Diagnosis & Treatment of Infectious Diseases (Zhejiang University) as primary investigator.

Asieris Appoints Dr. Linda Wu as Chief Development Officer

Retrieved on: 
火曜日, 1月 17, 2023
Linda, Molecular biology, Degenerative disease, Janssen, Shanghai Medical College, Group medical practice in the United States, University, Doctor of Philosophy, MS, Janssen Pharmaceuticals, Fudan University, Johnson & Johnson, Chinese Academy of Sciences, Prostate, BS, Drug discovery, Patient, Pharmacology, Biochemistry, Research, Shanghai Institute of Visual Art, GU, Bayer, Pharmaceutical industry, Cancer, Materia medica

SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.

Key Points: 
  • SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.
  • Dr. Wu will be based in the United States and report to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris.
  • Dr. Wu joins Asieris from Janssen Pharmaceuticals, a Johnson & Johnson company, where she most recently served as a Group Medical Director of Oncology, US Medical Affairs.
  • "I am thrilled and deeply honored to be appointed as Chief Development Officer at Asieris.

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

Retrieved on: 
火曜日, 12月 20, 2022
Hospital, Severe acute respiratory syndrome coronavirus 2, Ritonavir, Neuropsychiatric Disease and Treatment, SIMM, Chinese Academy of Sciences, Patient, National Medical Products Administration, Trial of the century, Clinical trial, Central nervous system, Phase, Simcere Pharmaceutical, Drug discovery, Biotechnology, Capacity building, Fatality, Health, Degenerative disease, III, China-Japan Friendship Hospital, COVID-19, Medicine, Technology transfer, Safety, Post-exposure prophylaxis, National Center for Advancing Translational Sciences, Peking Union Medical College, Infection, Wuhan Institute of Virology, WIV, Cancer, NDA, Fear, FPI, Viral load, New Drug Application, Wuhan Jinyintan Hospital, Research, CAS, Pharmaceutical industry, Materia medica, Study, Virology

Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.

Key Points: 
  • Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.
  • This is to fulfill the Group's corporate mission of "providing today's patients with medicines of the future".
  • The Study has established a total of 43 clinical research centers in 20 provinces, municipalities and autonomous regions in China.
  • XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

Conagen unveils commercial production of high-purity non-GMO salidroside

Retrieved on: 
火曜日, 9月 27, 2022
Rhodiola, Inflammation, Health, Stress management, Synthetic biology, Exercise, Oxidative stress, Technology, Cell, Solution, Food, Sleep, Water, GLOBE, Medicine, Fatigue, Compendium, Fermentation, Drink, Compendium of Materia Medica, Depression, Antioxidant, Food preservation, Dietary supplement, Materia medica

Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions which are available from their pipeline partner, Sweegen.

Key Points: 
  • Unlike other salidroside products currently on the market, Conagens salidroside is non-GMO.
  • Conagens 99% high-purity salidroside, made by bioconversion, is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal.
  • Salidroside is one of the rare, natural molecules with proven adaptogenic activities which correlates to stress reduction , said Lippmeier.
  • Conagen accelerated salidroside production by leveraging one of its proprietary molecular platforms, which have also been used to produce the clean antioxidants hydroxytyrosol and p-coumaric acid.

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Retrieved on: 
木曜日, 6月 2, 2022
LHON, Retina, Leadership, Nanjing University, Head, Company, CMO, Bachelor of Science, Johnson & Johnson, III, Doctor of Philosophy, AACR, Federation of European Pharmacological Societies, CEO, Scientific Reports, Partnership, Society, ASCO, ODD, IND, Multimedia, Chinese Academy of Sciences, AAV, US FDA, NMPA, Therapy, American Society of Clinical Oncology, FDA, Patient, EBioMedicine, AstraZeneca, American Association for Cancer Research, SAN, Clinical trial, Drug discovery, Efficiency, CPS, Shanghai Institute of Technology, CRO, CSCO, Medical device, Pharmaceutical industry, Ophthalmology, Chemistry, Materia medica, Nature, Pharmacology

SHANGHAI and SAN DIEGO, June 2, 2022 /PRNewswire/ --Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced the appointment of Xiaoning Guo, Ph.D., as the Chief Medical Officer (CMO).

Key Points: 
  • SHANGHAI and SAN DIEGO, June 2, 2022 /PRNewswire/ --Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced the appointment of Xiaoning Guo, Ph.D., as the Chief Medical Officer (CMO).
  • Dr. Xiaoning Guo will have overall responsibility for the drug development function, including clinical development, medical, and pipeline management.
  • He joins Neurophth from SciClone Pharmaceuticals, where he served as Head of R&D and Chief Medical Officer, leading the development of several drugs and clinical work.
  • Dr. Guo, Chief Medical Officer suggested that "Neurophth has been in the forefront of gene therapy for ocular disease.

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

Retrieved on: 
水曜日, 5月 25, 2022
Chinese Academy of Sciences, Junshi, Pharmacokinetics, Social responsibility, SSE, Shanghai Institute of Technology, Genoa Joint Laboratories, Bamlanivimab/etesevimab, Arm, Incidence, Phase, COVID-19, Bamlanivimab, Marketing, Research, GLOBE, Death, Lilly, Autoimmunity, R & D, Wuhan Institute of Virology, Infection, FDA, Physics, Communication, HKEX, Severe acute respiratory syndrome coronavirus 2, Neoplasm, Drug discovery, List of Nature Research journals, Belt, Patient, Microbiology, Ministry, Technology, NMPA, Safety, Transfusion-related acute lung injury, Absorption, Pharmaceutical industry, Medical device, Science, Virology, Chinese, Materia medica, Science, Chemistry

SHANGHAI, China, May 25, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 (JT001) provided patients with a shorter median time to sustained clinical recovery, achieving statistical superiority.

Key Points: 
  • The NCT05341609 study is a multicenter, single-blind, randomized, controlled Phase III study evaluating the efficacy and safety of VV116 (JT001) in comparison with PAXLOVID in the early treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death.
  • The results of this Phase III study, evaluating VV116 (JT001) as a treatment for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death, show that the predetermined primary endpoint has been reached.
  • VV116 is currently in an international, multicenter Phase III trial, and a number of clinical studies for mild, moderate and severe COVID-19 are in progress.
  • In 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19.

Hempu Time innovates CBD- and TCM-contained products with Yunnan Baiyao

Retrieved on: 
木曜日, 4月 21, 2022
CEO, Pains, Cannabidiol, Research, Spray, TCM, Shennong Ben Cao Jing, Textile, Inflammation, Cosmetics, Agriculture, Method, History, Animal, ECS, Agricultural science, Multimedia, Epilepsy, Chinese Academy of Sciences, Institute, View, Hemp, Chronic pain, Materia medica, Frankincense, Medicinal plants, CBD

Hempu Time Inc., a Chinese hemp company, has been promoting traditional Chinese medicine (TCM) and cannabidiol (CBD) by collaborating with Yunnan Baiyao, a time-honored TCM pharmaceutical company in China.

Key Points: 
  • Hempu Time Inc., a Chinese hemp company, has been promoting traditional Chinese medicine (TCM) and cannabidiol (CBD) by collaborating with Yunnan Baiyao, a time-honored TCM pharmaceutical company in China.
  • Hempu Time has synergized TCM and CBD in multiple products, launching its 1st CBD pain relieving spray with a subsidiary of Yunnan Baoyao in November 2021 and pain-away patches in February 2022.
  • Compared with ordinary topical sprays, the pain-relieving spray distributed by Hempu Time contains CBD, which is documented in studies to be effective in reducing inflammation and alleviating chronic pains.
  • According to a research conducted by Hempu Time and Yunnan Baiyao, the formulas combining TCM and CBD are conducive to releasing pains and maintaining the inner balance of bodies.

Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19

Retrieved on: 
水曜日, 3月 16, 2022
Bamlanivimab, Physics, Mortality, Pharmacokinetics, Microbiology, EUA, R & D, Autoimmunity, Development, Ministry, GLOBE, Patient, Chinese Academy of Sciences, Bamlanivimab/etesevimab, Eli Lilly, FDA, Therapy, COVID-19, Ministry of Science and Technology (Vietnam), SSE, Marketing, Safety, HKEX, NMPA, Drug discovery, Severe acute respiratory syndrome coronavirus 2, Wuhan Institute of Virology, Infection, Shanghai Institute of Technology, Belt, Pharmaceutical industry, Omicron, Chemistry, Materia medica, Science, Technology, Virology

The study is an international multicenter, randomized, double-blind, controlled Phase III study to evaluate the efficacy and safety of VV116 against standard therapy in subjects with moderate to severe COVID-19.

Key Points: 
  • The study is an international multicenter, randomized, double-blind, controlled Phase III study to evaluate the efficacy and safety of VV116 against standard therapy in subjects with moderate to severe COVID-19.
  • VV116 is an oral nucleoside analog anti-SARS-CoV-2 investigational drug jointly developed by Junshi Biosciences and Vigonvita Life Sciences Co., Ltd. (Vigonvita).
  • Junshi Biosciences and Vigonvita have completed three Phase I studies evaluating the safety, tolerability, and pharmacokinetics of VV116 in healthy Chinese subjects, with preliminary results showing good clinical safety.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Universe Pharmaceuticals INC Announces Strategic Alliance with Jiangxi Province Institute of Materia Medica to Conduct Research on Traditional Chinese Medicine

Retrieved on: 
火曜日, 1月 4, 2022
Universe, People, Particle-size distribution, INC, Dietary supplement, Compliance, Republic, GLOBE, Company, SEC, CEO, UPC, Ageing, Research, Marketing, Review, Nasdaq, Agreement, Pharmacopoeia, Phrase, Astragalus, Pharmaceutical industry, Medicinal plants, Materia medica, Epimedium

As part of the Agreements, both parties agreed to collaborate on scientific research, talents development, and project collaboration to further create formulas for traditional Chinese medicine.

Key Points: 
  • As part of the Agreements, both parties agreed to collaborate on scientific research, talents development, and project collaboration to further create formulas for traditional Chinese medicine.
  • Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, We are excited to partner with Jiangxi IMM.
  • Affiliated to the Jiangxi Province Medical Products Administration, Jiangxi Province Institute of Materia Medica was established in 1973.
  • The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.